Home › Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...
 

Keywords :   


Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...

2013-12-08 05:39:25| Biotech - Topix.net

Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase , for the treatment of patients with relapsed or refractory hematologic malignancies.

Tags: in results previously phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
05.07Simplestream reveals preferred technology partnership with Freely
More »